Navigation Links
Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics' Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
Date:12/10/2007

g to identify the maximum tolerated dose.

Tezampanel is the first AMPA/kainate antagonist to be studied in a clinical trial for acute migraine. Both tezampanel and the oral prodrug NGX426 represent a novel, non-opiod, non-vascular and non-serotonergic approach to treating multiple pain conditions, including migraine. Tezampanel and NGX426 are antagonists of a subgroup of glutamate receptors referred to as AMPA and kainate. These receptors are found in areas of the central and peripheral nervous system that are important for the transmission of pain. During a migraine attack, levels of glutamate increase and activate these receptors, facilitating the transmission of pain impulses. Tezampanel, by blocking the binding of glutamate to these receptors, is believed to inhibit the transmission of pain signals that lead to migraine headaches.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include statements regarding the potential for tezampanel as a treatment for migraine, the potential for NGX426 as a treatment for migraine, the potential for tezampanel to offer a unique approach to the management of pain, the potential for NGX426 to offer a unique approach to the management of pain
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
3. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
4. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
5. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
6. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Decision Resources, one of the world,s leading research ... finds that the cost of Roche/Chugai,s Avastin, followed ... are cited most frequently by surveyed oncologists as ... non-small-cell lung cancer treatment in Germany, France, Italy, ... Special European Physician & Payer Forum report entitled ...
(Date:12/17/2009)... ORLANDO, Fla., Dec. 17 MedX Limited, ... -branded medical exercise equipment and a subsidiary of ... the sale of 227 MedX exercise ... list of countries, including Australia, Germany, India, Scotland, ... sold MedX equipment will be used ...
(Date:12/17/2009)... Inc., (OTC Bulletin Board: SCIE) disclosed today that its ... letter to shareholders: ,, As the end of the ... the recent closing of a $4.3 million round of ... ramping our business performance as we head into 2010. ... force. We are increasing our sales and marketing activities ...
Breaking Medicine Technology:Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 2Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 3WellTek Subsidiary MedX Limited Increases Presence in Global Market 2WellTek Subsidiary MedX Limited Increases Presence in Global Market 3WellTek Subsidiary MedX Limited Increases Presence in Global Market 4SpectraScience Releases Shareholder Newsletter 2SpectraScience Releases Shareholder Newsletter 3SpectraScience Releases Shareholder Newsletter 4SpectraScience Releases Shareholder Newsletter 5Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 1Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 2Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 3Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 4Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 5Abbott Cuts Use of Oil and Coal by 35 Percent 5108 1Abbott Cuts Use of Oil and Coal by 35 Percent 5108 2Abbott Cuts Use of Oil and Coal by 35 Percent 5108 3Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth 5106 1Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth 5106 2
... American Association for Cancer Research,annual meeting -, ... Inc. today presented preclinical data demonstrating potent,anti- ... the,efficacy and safety in animal models of ... are both attractive targets,for an antibody-drug conjugate ...
... OncoGenex Technologies,Inc. announced today data from a Phase II ... with metastatic breast,cancer (MBC). Data was presented by the ... the American Association for,Cancer Research 2007 Annual Meeting in ... concluded:, - ...
Other Medicine Technology:Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 2Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 3Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 4OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 2OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 3OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 4
(Date:12/17/2009)... ,Hopenhagen, the city is calling itself, that is, ... on climate change. Narconon has its European management ... worldwide Narconon drug education and rehabilitation ... change. But the streets thrum with student drums ... flashing blue lights - a youth protest group ...
(Date:12/17/2009)... cast takes the stage at the Fisher Theatre on Dec. 17 ... patients and cancer survivors will be the real stars of the ... ... When the cast takes the stage at the Fisher Theatre on ... Boys,” Beaumont cancer patients and cancer survivors will be ...
(Date:12/17/2009)... Physicians, nurses now able to access trusted medical information using ... ... Marlborough, MA (PRWEB) December 17, 2009 -- Skyscape, Inc., the ... devices and the Internet, has launched a mobile clinical decision ... resources are now available on most smart phone devices, making ...
(Date:12/17/2009)... -- On the heels of unveiling the new Stadium ... race, LA Marathon officials today announced a larger-than-ever charity ... for causes ranging from cancer research to gang intervention ... program is in line with the vision of Marathon ... potential to be a huge philanthropic force in the ...
(Date:12/17/2009)... HONG KONG, Dec. 17 /PRNewswire-Asia/ -- China,s leading ... or "the,Group"; Stock Code: 801) is pleased to ... During the period under review, the Group,s two,associate ... Stock Exchange and NASDAQ;,its key businesses have been ... new hospital management operations. , ...
Breaking Medicine News(10 mins):Health News:Save the Planet. Stop Smoking Dope, Says Narconon 2Health News:Jersey Boys' Premiere Benefits Cancer Patients While Launching Beaumont Hospitals Fundraising Campaign 2Health News:Jersey Boys' Premiere Benefits Cancer Patients While Launching Beaumont Hospitals Fundraising Campaign 3Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 2Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 3Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 4Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 2Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 3Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 4Health News:Golden Meditech Announces Interim Results of FY2009/10 2Health News:Golden Meditech Announces Interim Results of FY2009/10 3
... Prize in Chemistry: William S. Knowles, previously at ... Nagoya University, Chikusa, Nagoya, Japan and K. Barry ... USA. They were awarded the Prize for their ... developed chiral catalysts for two important classes of ...
... are more than twice as likely to develop Alzheimer's Disease ... ,The study - the largest ever of its kind and ... develop Alzheimer's - followed 5,369 men and women aged 57 ... the most common form of dementia, before the study by ...
... threatening India, which is ill-equipped to cope, say experts. The ... is high, and rising, suggests health data. ,India has a ... prone to developing diabetes later in life, and are certainly ... leading to coronary heart disease. ,Part of the ...
... heart attack victims by quickly giving blood transfusions to those ... said this advice, if widely adopted, could save thousands of ... important as giving aspirin, beta blockers or clot-dissolving drugs, which ... ,The size of the benefit depends on how anemic ...
... A low-fat high-carbohydrate diet raises blood fats, unless ... a low-fat diet will reduce heart disease risk ... (LDL or 'bad' cholesterol). But a low-fat diet ... to get calories from somewhere). And it's becoming ...
... a malaria drug are being questioned by experts, who ... Manufacturer GlaxoSmithKline markets the anti-malarial drug Malarone (atovaquone and ... the aggressive falciparum strain of malaria, but the Drug ... Association – says the evidence for this is misleading. ...
Other Medicine News:Health News:Diabetes on the rise, 2
... The Modulus™ is ... instrument designed to give ... measuring fluorescence, luminescence, and ... a dedicated fluorometer, dedicated ...
... VISUCAM non-mydriatic fundus camera ... simplicity of fundus imaging. ... to set the standard ... features a unique combination ...
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
The Pediatric ThermoWrap™ is designed to fit the proportions of your young patient and wraps around the entire body, without interfering with the sterilized area of operation....
Medicine Products: